11 Amendments of Neoklis SYLIKIOTIS related to 2017/2254(INI)
Amendment 6 #
Draft opinion
Recital A
Recital A
A. whereas antimicrobial resistance (AMR)-related challenges will increase in the years ahead and effective action is reliant on two equally important strategies: on the one hand, continued, cross-sectoral investments in research & innovation (R&I) and, on the other hand, comprehensive strategies for timely tackling the excessive and inappropriate use of antimicrobials both in humans and animals, so that better tools, products and approaches can be developed following a One Health approach;
Amendment 14 #
Draft opinion
Recital A a (new)
Recital A a (new)
Aa. whereas excessive and inappropriate use of antibiotics both in humans and animals is turning AMR into a massive threat for the future of humankind;
Amendment 37 #
Draft opinion
Paragraph 1 a (new)
Paragraph 1 a (new)
1a. Emphasises the need to increase funding for R&I regarding the rare diseases (orphan drugs);
Amendment 39 #
Draft opinion
Paragraph 1 b (new)
Paragraph 1 b (new)
1b. Emphasises the need to increase the funding for different instruments under H2020 so as to boost the research for improving our knowledge on detection, emergence and spread of AMR, prevention measures and effective infection control;
Amendment 42 #
Draft opinion
Paragraph 1 c (new)
Paragraph 1 c (new)
1c. Recalls that the most rapid and cost-effective strategy for addressing AMR is to ensure the adequate and rational use of the existing antimicrobials; highlights that all actors involved in the antimicrobials life-cycle chain shall take responsibility and cooperate towards this goal, including in particular the pharmaceutical, health and livestock industries; calls on the Commission to update and strengthen its guidelines and requirements for a prudent and rational use of antimicrobials in humans and animals;
Amendment 52 #
Draft opinion
Paragraph 2 a (new)
Paragraph 2 a (new)
2a. Calls on the Commission to ensure that substantial R&D efforts are made for increasing knowledge and properly assessing the role of the human, animal and manufacturing waste streams play in the development and spread of AMR, as foreseen in the One-Health action plan;
Amendment 61 #
Draft opinion
Paragraph 3
Paragraph 3
3. Emphasises that the EU should be at the forefront of the fight to address AMR, providing practical guidance to ensure sustainable effective action, in line with the Global Action Plan agreed by the World Health Assembly in 2015; expresses the urgent need to foster partnerships throughout the EU in order to enhance the exchange of best practices and improve knowledge on AMR;
Amendment 68 #
Draft opinion
Paragraph 3 a (new)
Paragraph 3 a (new)
3a. Underlines that the EU should co- fund the Member States so as to help them establish and implement their national One-Health action plans against AMR;
Amendment 74 #
Draft opinion
Paragraph 4 a (new)
Paragraph 4 a (new)
4a. Stresses the importance to improve awareness and understanding of AMR through effective sanitation, prevention measures, education and training, including EU public awareness campaigns and targeted training for health professionals, pharmacists, veterinaries and livestock breeders;
Amendment 82 #
Draft opinion
Paragraph 5 a (new)
Paragraph 5 a (new)
5a. Underlines the significant part that the pharmaceutical industry shall play in this long-term effort on Combating AMR. Calls on the Commission to further explore the requirements of this contribution by the pharmaceutical industry, namely, interalia, by asking for AMR information in the labelling of antimicrobial products and involving the industry in the monitoring and evaluation of the average use of each commercialized product;
Amendment 88 #
Draft opinion
Paragraph 5 b (new)
Paragraph 5 b (new)
5b. Recalls, as stated in the Commission Guidelines for the prudent use of antimicrobials in veterinary medicine, that the untargeted use of antimicrobials, its use in sub-therapeutic doses and its use for inappropriate periods of time severely increases the risk of development of AMR; stresses that the EU livestock industry must remain a global leader in phasing out the misuse of antimicrobials as a matter of routine, specially through feed and drinking water, and calls on the Commission for further strengthening the requirements for the use of antimicrobials in the livestock industry;